USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad

NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced conclusion of US FDA Inspection at our Mekaguda, Hyderabad Active Pharmaceutical Ingredients (API) Unit.

The U.S. Food and Drug Administration (FDA) had conducted an inspection at the API manufacturing plant located in Mekaguda, Hyderabad, India, which was conducted from June 9th - June 13th, 2025.

On conclusion of the inspection, the Company received 1 (One) observation in the Form-483. The Company believes that the observation is procedural in nature. The Company is confident to address this observation comprehensively.

Company remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 924.15 as compared to the previous close of Rs. 934.25. The total number of shares traded during the day was 230057 in over 9711 trades.

The stock hit an intraday high of Rs. 955.00 and intraday low of 918.45. The net turnover during the day was Rs. 215694023.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 USFDA Inspection APIManufacturingPlant Mekaguda Hyderabad